CVS Caremark Corporation: Q1 2009 10-Q Summary
Business Context and Reporting Period
This filing covers the fiscal quarter ended March 31, 2009. CVS Caremark Corporation operates as a fully integrated pharmacy services company with two primary segments: Pharmacy Services (PBM, mail order, specialty pharmacy) and Retail Pharmacy (6,912 stores including CVS/pharmacy and Longs Drug). The company recently changed its fiscal year-end to December 31, 2008, to align with the healthcare industry rather than retail. The 2009 quarter included 90 days, compared to 91 days in the prior year.
Key Financial Metrics
| Metric (in millions) | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Revenues | $23,393.9 | $21,326.0 |
| Gross Profit | $4,748.0 | $4,293.0 |
| Operating Profit | $1,377.2 | $1,370.1 |
| Net Earnings | $738.4 | $748.5 |
| Diluted EPS | $0.50 | $0.51 |
| Operating Cash Flow | $771.3 | $740.8 |
| Cash & Equivalents | $997.4 | $1,352.4 (Dec 31, 2008) |
| Total Debt (Short + Long Term) | $11,127.6 | $11,754.6 (Dec 31, 2008) |
Note: Total Debt calculated as Short-term debt ($1,419.9M) + Current portion of long-term debt ($651.4M) + Long-term debt ($9,056.3M).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $2.1 billion (9.7%). This was driven primarily by the Longs Drug Stores acquisition (effective Oct 2008), which added approximately $1.4 billion in revenue. The inclusion of RxAmerica results also contributed to growth in the Pharmacy Services segment.
- Profitability: While gross profit increased by $455 million, net earnings declined slightly by $10.1 million (1.3%). This decrease was due to higher operating expenses related to the Longs integration, increased interest expense from debt used to fund the acquisition, and a $5.1 million loss from discontinued operations (lease guarantees for former subsidiaries like Linens 'n Things).
- Segment Performance:
- Pharmacy Services: Revenue rose 7.2% to $11.5 billion. Operating profit margin compressed to 4.2% from 4.9% due to litigation reserves and the dissolution of a joint venture.
- Retail Pharmacy: Revenue rose 13.9% to $13.5 billion. Same-store sales increased 3.3%, though front-store sales were negatively impacted by a later Easter holiday.
- Debt Structure: The company issued $1.0 billion in 6.60% senior notes due 2019 to repay bridge financing and commercial paper used for the Longs acquisition.
Outlook, Risks, and Management Commentary
- Guidance & Plans: Management plans to open 150–200 new or relocated retail pharmacy stores for the remainder of 2009. The quarterly dividend was increased by 10.5% to $0.07625 per share.
- Market Risks: The company faces pressure from third-party payors reducing reimbursement rates, particularly for generic drugs. There is also uncertainty regarding the implementation of the Deficit Reduction Act (DRA) and Average Manufacturer Price (AMP) rules affecting Medicaid reimbursements.
- Legal Contingencies: Significant litigation includes a qui tam lawsuit regarding Medicaid claims processing (with recent favorable rulings but ongoing appeals) and a putative class action seeking $3.2 billion related to insurance coverage misrepresentation. The company also guarantees leases for approximately 95 former subsidiary stores.
- Accounting Changes: The company adopted SFAS 141(R) for business combinations and EITF 08-3 for maintenance deposits, though these had no material impact on current results.
Investor Verification Checklist
- Integration Synergies: Verify the timeline and realization of cost synergies from the Longs Drug Stores and Caremark mergers.
- Reimbursement Trends: Monitor the impact of generic drug conversion rates and third-party payer reimbursement cuts on gross profit margins.
- Legal Exposure: Track developments in the Medicaid qui tam litigation and the $3.2 billion class action lawsuit.
- Debt Servicing: Assess the impact of the new $1.0 billion senior note issuance on future interest expenses and cash flow.
- Regulatory Changes: Watch for final rulings on the AMP Rule and its effect on Medicaid reimbursement formulas.